Literature DB >> 6517540

Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.

J J Kirsi, P A McKernan, N J Burns, J A North, B K Murray, R K Robins.   

Abstract

The antiviral effects of selenazofurin (2-beta-D-ribofuranosylselenazole-4-carboxamide, selenazole), ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), and 3-deazaguanosine (6-amino-1-beta-D-ribofuranosylimidazo-[4.5-C]pyridin-4(5H)-one) were investigated separately and in various combinations in an in vitro study. The combination interactions were evaluated at seven drug concentrations, graphically (isobolograms) or by using fractional inhibitory concentration indices against mumps, measles, parainfluenza virus type 3, vaccinia and herpes simplex virus type 2 viruses in Vero and HeLa cells. Selenazofurin in combination with ribavirin produced the greatest synergistic antiviral activity. However, the degree of synergy depended on the virus and cell line used. In contrast, selenazofurin combined with 3-deazaguanosine consistently yielded an indifferent or an antagonistic response, or both, whereas the ribavirin-3-deazaguanosine interaction was additive against the same viruses. Single-drug cytotoxicity was minimal for the cytostatic agents selenazofurin and ribavirin but was markedly higher for cytocidal 3-deazaguanosine, as determined by relative plating efficiency after drug exposure. The drug combinations did not significantly increase cytotoxicity (they were only additive) when used on uninfected cells. Therefore, the enhanced antiviral activities of the drug combinations (shown to be synergistic) were due to specific effects against viral replication. These results indicated that in Vero and HeLa cells (i) the combination of selenazofurin and ribavirin produced an enhanced antiviral effect, thus requiring smaller amounts of drug to cause the same antiviral effect relative to a single compound; (ii) selenazofurin when compared with ribavirin and 3-deazaguanosine appeared to have a somewhat different mode of antiviral action; (iii) 3-deazaguanosine combined with selenazofurin was an unsuitable antiviral combination; and (iv) the antiviral activity of 3-deazaguanosine appeared to be due largely to its general overall cytotoxic effect.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6517540      PMCID: PMC179946          DOI: 10.1128/AAC.26.4.466

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

2.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.

Authors:  B B Goswami; E Borek; O K Sharma; J Fujitaki; R A Smith
Journal:  Biochem Biophys Res Commun       Date:  1979-08-13       Impact factor: 3.575

3.  Antiviral, immunosuppressive and antitumour effects of ribavirin.

Authors:  C W Potter; J P Phair; L Vodinelich; R Fenton; R Jennings
Journal:  Nature       Date:  1976-02-12       Impact factor: 49.962

4.  Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent.

Authors:  W E Müller; A Maidhof; H Taschner; R K Zahn
Journal:  Biochem Pharmacol       Date:  1977-06-01       Impact factor: 5.858

5.  Conversion of 2-beta-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties.

Authors:  H N Jayaram; G S Ahluwalia; R L Dion; G Gebeyehu; V E Marquez; J A Kelley; R K Robins; D A Cooney; D G Johns
Journal:  Biochem Pharmacol       Date:  1983-09-01       Impact factor: 5.858

6.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

7.  Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.

Authors:  P D Cook; L B Allen; D G Streeter; J H Huffman; R W Sidwell; R K Robins
Journal:  J Med Chem       Date:  1978-12       Impact factor: 7.446

8.  Enhancement of activity against influenza viruses by combinations of antiviral agents.

Authors:  F G Hayden; R G Douglas; R Simons
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

9.  Synthesis and antitumor activity of 2-beta-D-ribofuranosylselenazole-4- carboxamide and related derivatives.

Authors:  P C Srivastava; R K Robins
Journal:  J Med Chem       Date:  1983-03       Impact factor: 7.446

10.  Reversible inhibition of cellular metabolism by ribavirin.

Authors:  A Larsson; K Stenberg; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

View more
  5 in total

1.  Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses.

Authors:  J W Huggins; R K Robins; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

2.  Effects of selenazofurin and ribavirin and their 5'-triphosphates on replicative functions of influenza A and B viruses.

Authors:  S K Wray; R H Smith; B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

Review 3.  Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story.

Authors:  Rand Naffouje; Punita Grover; Hongyang Yu; Arun Sendilnathan; Kara Wolfe; Nazanin Majd; Eric P Smith; Koh Takeuchi; Toshiya Senda; Satoshi Kofuji; Atsuo T Sasaki
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639

Review 4.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

5.  Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.

Authors:  Robert O Baker; Mike Bray; John W Huggins
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 10.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.